Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study Assessing Durability of Different Initial Regimens in Patients Starting Antiretroviral-Therapy (ART) with Very Low CD4+ Counts, and High Viral Load

Trial Profile

A Study Assessing Durability of Different Initial Regimens in Patients Starting Antiretroviral-Therapy (ART) with Very Low CD4+ Counts, and High Viral Load

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Apr 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atazanavir/ritonavir (Primary) ; Cobicistat/darunavir (Primary) ; Darunavir/ritonavir (Primary) ; Dolutegravir (Primary) ; Efavirenz (Primary) ; Elvitegravir (Primary) ; Entecavir (Primary) ; Fosamprenavir (Primary) ; Lamivudine/abacavir (Primary) ; Nevirapine (Primary) ; Raltegravir (Primary) ; Rilpivirine (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 Apr 2018 New trial record
    • 07 Mar 2018 Results presented at the 25th Conference on Retroviruses and Opportunistic Infections.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top